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Abstract: Transforming growth factor (TGF)-β inhibits hepatitis B virus (HBV) replication although
the intracellular effectors involved are not determined. Here, we report that reduction of
HBV transcripts by TGF-β is dependent on AID expression which significantly
decreases both HBV transcripts and viral DNA, resulting in inhibition of viral replication.
Immunoprecipitation reveals that AID physically associates with viral P protein that
binds to specific virus RNA sequence called epsilon. AID also binds to an RNA
degradation complex (RNA exosome proteins), indicating that AID, RNA exosome, and
P protein form a RNP complex. Suppression of HBV transcripts by TGF-β was
abrogated by depletion of either AID or RNA exosome components, suggesting that
AID and the RNA exosome involve in TGF-β mediated suppression of HBV RNA.
Moreover, AID-mediated HBV reduction does not occur when P protein is disrupted or
when viral transcription is inhibited. These results suggest that induced expression of
AID by TGF-β causes recruitment of the RNA exosome to viral RNP complex and the
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RNA exosome degrades HBV RNA in a transcription-coupled manner.
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We appreciate all reviewers’ comments and questions, which greatly improved 
our manuscript. The reviewers’ comments are in italics below.  
 
Reviewer #1: In the revised submission Liang et al. have addressed many of the 
earlier concerns however some of the most important concerns still remain 
unaddressed.   
 
HBV replicon cells do not represent a good model system to study host cell 
response to HBV infection. The observation made with replicon cells should 
be further substantiated using cell culture models which resemble natural 
HBV infection or in HBV stable cell lines harboring integrated HBV 
transgene.  This is essential to rule out any AID-mediated effect on 
transfected HBV plasmid and to ascertain that the observed inhibition of 
HBV replication is a post-transcriptional event.   
 
Response 
Thanks for reminding us this important question. As shown in our results, 
experiments using HBV stable cell lines harboring an integrated HBV transgene 
were performed. First, a B cell line containing a chromosomally integrated HBV 
transgene (Fig. 3I–K) demonstrated that endogenous AID expression induced 
by cytokine stimulation (CIT) downregulates HBV RNA. Second, experiments 
using 7T7-8 cells, a stable Huh7 cell line that has the chromosomally integrated 
HBV transgene, demonstrated that TGF-1 downregulates HBV RNA and 
TGF-1-mediated downregulation of HBV RNA is dependent on AID and Exosc3 
(Fig. 7). Thus, we think that the experiments requested by reviewer 1 have been 
done. 
 
In addition, we would like to add other evidences to strengthen our conclusion. 
In this study, we excluded the possibility of an AID-mediated effect on 
transfected HBV plasmid based on three pieces of experimental evidence. 
(1) The two HBV stable cell lines mentioned above rule out any artifacts due to 
transient transfection. (2) AID- and TGF-1-mediated HBV reductions were 
rescued by knocking down of RNA exosome proteins. (3) AID-mediated HBV 
Response to Reviewers
  
reduction was no longer observed in the absence of intact HBV P protein, which 
cannot be explained by an AID-mediated effect on the HBV plasmid. If AID 
affects plasmids, AID should also affect the HBV P protein mutant replicon. 
However, we did not observe AID-mediate HBV RNA downregulation in the 
mutant replicon.  
 
As for an in vitro model mimicking natural HBV infection, our collaborator 
previously demonstrated that AID expression is induced by IL-1 stimulation in 
HBV-infected HepaRG cells and IL-1 restricts HBV replication in infected 
HepaRG cells. Moreover, Dr. Watashi showed that AID is essential for the 
antiviral activity of IL-1 (JBC 2013, Watashi et al.). Therefore, involvement of 
AID in an antiviral pathway against HBV was suggested using a HepaRG model 
of natural HBV infection in our previous collaborative study; however, the 
molecular mechanism by which AID suppresses HBV replication was not 
determined at that time.  
 
To further confirm the involvement of AID in TGF--mediated restriction of HBV 
replication in an HBV infection model, we asked our previous collaborators, Drs. 
Wakita and Watashi, to send an HBV-producing cell line and NTCP-expressing 
HepG2 cells. Wakita’s group has demonstrated that they can infect their 
NTCP-expressing HepG2 cells with HBV (BBRC 2013, 440:515). Those cell 
lines were received by us very recently (in Japan, material transfer of infectious 
research tool is time-consuming), and we performed a preliminary experiment of 
HBV infection by using their protocol, the results of which are shown below.  
    
NTCP-expressing HepG2 cells were 
seeded with medium containing 4% 
DMSO. HBV was concentrated in PEG. 
NTCP-expressing HepG2 cells were 
infected with HBV (8000 genome 
equivalent / cell). One day after 
infection, one group was treated with 
  
TGF- and the other was not treated. After 3 days of TGF- treatment, cells 
were harvested for RT-qPCR to determine AID, GAPDH, and HBV mRNA levels. 
Non-infected-NTCP HepG2 cells (treated with only PEG) were also used as a 
control. After normalization to GAPDH levels, the fold induction of AID and HBV 
RNA were determined. Cells infected with HBV but without TGF- treatment 
were defined as one-fold induction.  
 
The results above indicate that TGF- upregulates AID mRNA, and 
TGF-reduces HBV RNA levels in HBV-infected NTCP-HepG2 cells, which is 
consistent with our major claim in the manuscript; that is, AID downregulates 
HBV transcripts.  
 
In summary, experimental evidence from two HBV stable cell lines (Figs. 3I–K 
and 7) and two natural infection models (attached Fig. 1, and our previous paper 
JBC 2013 Watashi et al.), ruled out an AID effect on transfected plasmid, and 
those results are consistent with AID-mediated HBV RNA reduction. 
 
Reviewer #1 
It is also important to consider viral escape strategies involving TGFb signaling 




Thank you for intriguing comment.  
AID-mediated HBV RNA reduction depends on HBV P protein (Fig. 4C). 
Logically, the more efficiently AID reduces HBV RNA, the lower the level of P 
protein. Under the condition where P protein is limiting, AID-mediated HBV RNA 
downregulation is relatively inefficient. We think that reducing the copy number 
of HBV genome per cell is a plausible escape mechanism in HBV infection. 
It would be also possible for HBV to develop other escape mechanisms.  




2) The microscopic analysis done is very weak. Proper confocal 
microscopy should be performed and images need to be captured at higher 
magnification to be able to properly discern various subcellular sites and 
precisely determine the colocalization between HBV P protein and AID.  
 
Response 
We do not have access to a confocal microscope; thus, we tried very hard to 
detect AID and HBV P proteins by immunostaining using conventional 
fluorescence microscopy (together with the approach using GFP and DsRed 
fusion proteins, which was shown in the first revision). 
However, high background fluorescence and/or low specific signals of AID and P 
proteins prevented us from conclusively interpreting the results.  
Meanwhile, we demonstrated a complex formation between AID and P proteins 
by immunoprecipitation following subcellular fractionation (Supplementary Fig. 
3).  
Those results indicate that AID and P proteins form complexes in both the 
nucleus and cytoplasm. Moreover, we also determined the subcellular fraction 
containing the AID/exsoc3/HBV-RNA complex (Fig. 5 and Supplementary Fig. 4). 
Since AID-mediated HBV RNA reduction was observed in the nuclear fraction 
(Supplementary Fig. 6), we think that AID, P protein, RNA exosomes, and HBV 
RNA form RNP complexes in both the nucleus and cytoplasm, and that RNA 
degradation occurs at least in the nucleus. 
 
Reviewer #1 
3) According to the authors AID and HBV P interact both in the cytoplasm 
and nucleus and all the HBV transcripts are likely affected. Which subcellular 
site is predominantly responsible for AID mediated degradation of HBV pgRNA.  
 
Response 
We appreciate this important question. Because AID, P protein, RNA exosome 
as well as HBV RNA molecules distribute to both nucleus and cytoplasm, it is not 
easy to conclude which subcellular site is predominantly responsible for AID 
mediated HBV RNA reduction. 
  
To this end, we biochemically fractionated nuclear RNA and cytoplasmic RNA 
and determined the subcellular fractions in which AID reduces HBV RNA. The 
results show that AID-dependent HBV RNA reduction is observed in both 
fractions. Since nuclear RNA is an upstream of cytoplasmic RNA, we think that 
nuclear HBV RNA may be a primary target for AID-mediated RNA reduction. In 
the revised manuscript, these results are shown as Supplementary Fig. 6, and 
the main text was modified accordingly (lines 244–248, in red). 
However, we do not exclude that AID also triggers cytoplasmic viral RNA decay. 
To conclude this, we need to find a condition that AID does not induce viral 
nuclear RNA but cytoplasmic RNA decay. At present, we have not found such a 
condition (like use mutant HBV, AID mutant or inhibition of AID nuclear export), 








Northern blotting in Fig. 4 demonstrates that AID expression reduces all types of 
HBV RNA in the presence of P protein while AID does not change the pattern of 
HBV RNA, as detected by northern blot, in the absence of P protein. In the 1st 
revised manuscript, we showed that all of HBV transcripts contain the eplison 
RNA structure that HBV P protein binds to.  Therefore, HBV P protein is 









This is an important analysis that we are also very interested. However, to add 
any relevant information from clinical samples, we would need to obtain RNA 
samples from liver biopsies within a very short period, which is not feasible. 
Again, Japan has strict relevant laws not letting us to obtain patients’ samples in 
a short time. 
Moreover, to add supportive evidence of AID-mediated HBV RNA reduction, we 
would need two types of liver samples (high and low AID expression). 
Unfortunately, useful SNP markers associated with differential expression of AID 
or AID-deficient patients are not available in the public data base. 
 
Reviewer #1 
5) Recently a similar mechanism involving ZAP protein mediated 
posttranscriptional degradation of HBV RNA has been reported (Mao et al, PLos 
Pathogens, 2013, e1003494). Is ZAP involved in AID mediated degradation of 
HBV RNA, the authors should silence ZAP and determine if AID activity is 
affected or not.  
 
Response 
Thank you for the excellent suggestion. 
According to the study by Mao et al. (Plos Pathogenes 2013), transcriptional 
upregulation of ZAP expression by either IFN or IPS-1 is important for 
ZAP-mediated HBV RNA reduction, especially for the ZAP short form. To 
explore the potential involvement of ZAP in AID-mediated HBV RNA reduction, 
we determined ZAP mRNA expression levels, and RT-qPCR shows no change 
in ZAP expression by AID expression. These results are included in 
Supplementary Fig. 2. 
 
Next, as recommended by reviewer #1, we knocked down ZAP expression using 
siRNAs. The results demonstrated that knocking down of ZAP increases basal 
HBV RNA levels; however, it did not affect AID-mediated HBV RNA reduction. 
We think that ZAP is dispensable for AID-mediated HBV RNA reduction. These 
results will help readers to understand AID-mediated HBV RNA reduction; 
therefore, we mention knocking down of ZAP in the Discussion and the results 
  
are shown as Supplementary Fig. 8 in the revised manuscript. (See lines 342–
351 in red) 
 
Reviewer #2:  
The authors answered all my questions. Most of the new data provided are 
satisfied, except for the following two points. 
 
In Figure 2A, loading of the first lane has problem because the loading 
control GAPDH in this lane is much weaker than other lanes. The new figure 
is needed to replace this one. 
 
Response 
Thanks for this reminding.  
We repeated the western blot and reconfirmed expression of FLAG-A3 proteins 
as well as GAPDH. Revised Fig. 2 was updated by replacing with new blots. 
 
Reviewer #2 
2) In Figure 5A, the labeling of the third lane is wrong, GFP-Exosec3 should be 
positive in this lane. 
 
Response 
Thank you very much. We corrected it. 
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Abstract 16 
Transforming growth factor (TGF)-β inhibits hepatitis B virus (HBV) replication although 17 
the intracellular effectors involved are not determined. Here, we report that reduction of HBV 18 
transcripts by TGF-β is dependent on AID expression, which significantly decreases both 19 
HBV transcripts and viral DNA, resulting in inhibition of viral replication. 20 
Immunoprecipitation reveals that AID physically associates with viral P protein that binds to 21 
specific virus RNA sequence called epsilon. AID also binds to an RNA degradation complex 22 
(RNA exosome proteins), indicating that AID, RNA exosome, and P protein form an RNP 23 
complex. Suppression of HBV transcripts by TGF-β was abrogated by depletion of either 24 
AID or RNA exosome components, suggesting that AID and the RNA exosome involve in 25 
TGF-β mediated suppression of HBV RNA. Moreover, AID-mediated HBV reduction does 26 
not occur when P protein is disrupted or when viral transcription is inhibited. These results 27 
suggest that induced expression of AID by TGF-β causes recruitment of the RNA exosome 28 
to viral RNP complex and the RNA exosome degrades HBV RNA in a transcription-coupled 29 














Hepatitis B virus (HBV) is recognized as the major causative factor of severe liver diseases 43 
such as cirrhosis and hepatocellular carcinoma. The clinical outcomes and development of 44 
hepatocellular carcinoma and cirrhosis are modulated by viral replication and antiviral 45 
immunity against HBV [1]. After entry into the host hepatocyte, HBV forms covalently 46 
closed circular DNA (cccDNA) in the nucleus and it initiates the transcription of viral RNAs, 47 
including a replicative intermediate known as pregenomic (pg) RNA. Two viral proteins 48 
(core and P protein) encapsidate pgRNA to form nucleocapsids, where P protein reverse-49 
transcribes pgRNA to produce relaxed circular (RC)-DNA. These nucleocapsids associate 50 
with three types of viral surface proteins for secretion as infectious virions [1,2]. Although 51 
the mechanism of HBV replication has been well studied, the mechanisms of antiviral 52 
immunity against HBV remain unclear. 53 
 54 
Several members of the apolipoprotein B mRNA editing enzyme catalytic polypeptide 55 
(APOBEC) family were recently identified as new types of antiviral factors [3-5]. In humans, 56 
the APOBEC family comprises at least 11 members, including activation-induced cytidine 57 
deaminase (AID), APOBEC 1, 2, 3A, 3B, 3C, 3D, 3F, 3G, 3H, and 4. Most family members 58 
deaminate cytidine bases on DNA and/or RNA to generate uridine [3-5]. Accumulating 59 
evidence from in vitro experiments has further revealed that A3 proteins can inhibit the 60 
replication of various types of viruses, including human immunodeficiency virus type 1 61 
(HIV-1) and HBV [4,5]. Among APOBEC deaminases, the molecular mechanism of A3G 62 
antiviral activity has been well characterized. In cases of HBV, A3G restricts viral replication 63 
through hypermutation and inhibition of reverse-transcription [4,5]. AID is another member 64 
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of the APOBEC family [4,5] and was originally isolated as a cytidine deaminase that 65 
triggered class switch recombination (CSR) and somatic hypermutation (SHM) of transcribed 66 
immunoglobulin genes in B cells [6-9]. AID expression was recently shown to be upregulated 67 
in human hepatocytes in vitro after stimulation with cytokines, including TGF-β1, TNFα, 68 
and IL-1β and in the liver in chronic hepatitis patients, and AID involvement in viral 69 
infection was suggested [10-17]. Higher serum TGF-β1 levels were reported in some HBV 70 
infections in vivo [18,19], and TGF-β1 reduces HBV replication in vitro [18,20]. However, 71 
the precise mechanisms remain elusive. In the present study, we examined the involvement of 72 
AID in TGF-β1-mediated restriction of HBV replication. We have demonstrated that TGF-73 
β1 induces AID expression in hepatocytes, which leads to the downregulation of HBV 74 
transcripts and inhibition of nucleocapsid formation. AID-dependent downregulation of HBV 75 
transcripts requires a viral RNA binding protein (P protein) and RNA exosome components. 76 
These data suggest a novel antiviral pathway in which AID recruits the RNA exosome to 77 
downregulate viral RNA in HBV infected hepatocytes. 78 
 79 
Results 80 
TGF-β1-mediated anti-HBV activity 81 
To investigate the involvement of APOBEC deaminases in TGF-β1-mediated antiviral 82 
activity against HBV, human hepatocytes (Huh7) were transfected with a HBV replicon 83 
plasmid (pPB) [21] and the cells were then treated with TGF-β1. Concentrations of 5–20 84 
ng/mL TGF-β1 were used to match the range reported in chronic HBV and hepatocellular 85 
carcinoma patients [19]. HBV replication was evaluated by measuring HBV transcript levels 86 
using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) (Fig. 1A) and 87 
Northern blotting (Fig. 1D). Viral DNA in secreted virions was determined using qPCR (Fig. 88 
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1B), and nucleocapsid formation was estimated using native agarose gel electrophoresis 89 
(NAGE). Subsequently, cytoplasmic nucleocapsid core protein and nucleocapsid associated 90 
DNA (NC-DNA) levels were determined using western blotting and Southern blotting, 91 
respectively (Fig. 1C). Collectively, TGF-β1 dose-dependently inhibited the production of 92 
HBV transcripts, nucleocapsid core protein, and nucleocapsid NC-DNA in both cytoplasmic 93 
and secreted samples.  94 
 95 
In further experiments, qRT-PCR was used to determine the expression of APOBEC 96 
deaminases in the presence and absence of TGF-β1. Initially, relative expression levels of 97 
APOBEC deaminases in non-stimulated Huh7 cells were determined. Huh7 cells expressed 98 
all APOBEC3 deaminases. A3G and A3C were highly expressed among A3 deaminases (Fig. 99 
1E), whereas APOBEC1 expression was not detected in Huh7 cells. In TGF-β1-treated 100 
Huh7 cells, expression of most APOBEC deaminases, including A3A, A3B, A3C, A3F, and 101 
AID (Fig. 1F, upper and lower) was upregulated. Western blotting also detected AID protein 102 
in TGF-β1-stimulated Huh7 cells (Fig. 1G). 103 
 104 
TGF-β1-mediated reduction of HBV transcripts depends on AID expression 105 
It has been demonstrated that APOBEC3 proteins suppress HBV replication in vitro [1,4,5]. 106 
HBV plasmids and APOBEC deaminase expression vectors were transfected into Huh7 cells, 107 
and nucleocaspid formation was estimated using NAGE followed by Southern and western 108 
blotting (NAGE assay). The expression of A3G and A3F, but not A3A, reduced NC-DNA 109 
levels in cytoplasmic nucleocapsids but did not reduce nucleocapsid core protein levels (Fig. 110 
2A). HBV virion DNA was also reduced by A3C, A3G and A3F expression, whereas total 111 
HBV transcript levels were not affected by A3C, A3G or A3F (Fig. 2B and C). It was 112 
proposed that minus-strand DNA synthesis was the primary target of A3G-mediated anti-113 
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HBV activity in hepatocytes that were transiently transfected with HBV plasmids [1,4,5]. Our 114 
results support this proposed mechanism of A3G antiviral activity. In contrast with A3 115 
deaminases, the overexpression of AID reduced HBV transcript levels, nucleocapsid 116 
formation, and virion secretion (Fig. 2A-C and Supplementary Fig. 1A and B). Nucleocapsid 117 
NC-DNA levels were also reduced in AID-expressing cells, as indicated by Southern blotting 118 
using purified nucleocapsid NC-DNA (Fig. 2D). Importantly, AID expression did not 119 
suppress host cell gene transcripts (Supplementary Fig. 2), suggesting that AID expression 120 
may specifically suppress viral RNA. In accordance with the HBV life cycle, these data 121 
suggest that AID-mediated reduction of HBV transcripts leads to the downregulation of 122 
nucleocapsid core protein and NC-DNA.  123 
 124 
To investigate the contributions of APOBEC deaminases to TGF-β1-mediated anti-HBV 125 
activity, small interfering (si) RNAs targeting specific deaminases were transfected with the 126 
HBV plasmid into Huh7 cells. Cells were further treated with TGF-β1 to assess the effects 127 
on TGF-β 1-mediated reduction of HBV transcripts. TGF-β 1 stimulation in siGFP-128 
transfected control cells reduced HBV transcript levels by 76% compared with non-129 
stimulated cells (Fig. 2E, top, lane 4 vs. 8). Transfection of siAID, siA3A, or siA3G 130 
suppressed the corresponding endogenous genes by up to 51%, 40%, and 56%, respectively. 131 
However, the knockdown of A3A and A3G did not affect TGF-β1-mediated reduction of 132 
HBV RNA in comparison with the siGFP control. In contrast, TGF- β 1-mediated 133 
downregulation of HBV RNA was significantly attenuated by the knockdown of AID (Fig. 134 
2E, top, lane 1 vs. 4). These data suggest that TGF-β1-mediated downregulation of HBV 135 
transcripts is dependent on endogenous AID expression. Partial rescue of HBV transcript 136 
levels in siAID-transfected cells also suggests the involvement of either residual AID or other 137 
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unidentified effectors in TGF-β1-mediated reduction of HBV transcripts. 138 
 139 
AID expression levels required for initiating class switching are sufficient for AID-140 
mediated reduction of HBV transcripts 141 
We previously demonstrated that the induction of AID in B cells triggers class switch 142 
recombination (CSR) in immunoglobulin genes [7-9], which validates B cells as a model to 143 
study AID functions. In addition, it is anticipated that peripheral blood mononuclear cells and 144 
B cells can be extrahepatic reservoirs for HBV infection [22,23]. Thus, we investigated 145 
whether endogenous AID expression that could trigger CSR is also sufficient to trigger a 146 
reduction in HBV transcripts. AID expression and IgA class switching can be induced in 147 
CH12F3-2 mouse B cells following co-stimulation with CD40 ligand, IL-4, and TGF-β1 148 
(designated CIT) [6,24]. CH12F3-2 cells transiently transfected with the HBV plasmid were 149 
divided into two groups, and were treated with (or without) CIT to induce IgA switching, a 150 
GFP expression vector was co-transfected to verify transfection efficiency. At three days 151 
post-transfection, HBV replication and CSR were determined (Fig. 3A-D), and showed that 152 
CIT induced AID protein expression and initiated IgA class switching, as previously reported 153 
[6,24]. Moreover, NAGE assays and qRT-PCR revealed that HBV transcripts, nucleocapsid 154 
NC-DNA, and core protein were downregulated in CIT-stimulated cells, whereas the 155 
expression of GFP remained intact after CIT stimulation (Fig. 3B, C). These data indicate 156 
that CIT stimulation specifically inhibits HBV replication in mouse B cells. We further used 157 
siRNAs against mouse AID (simAID-1 and -2) to assess the contribution of AID to the 158 
suppression of HBV products in CIT-stimulated cells. Although simAIDs knocked down 159 
endogenous AID transcripts to only 39% determined by qRT-PCR (Fig. 3E), western blotting 160 
revealed clear suppression of endogenous AID protein levels (Fig. 3F). Furthermore, flow 161 
cytometric analyses revealed that IgA class switching is attenuated by the knockdown of AID 162 
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(Fig. 3G), and qRT-PCR revealed that HBV transcript levels are inversely correlated with 163 
AID expression and IgA switching efficiency (Fig. 3G, H). To avoid artifacts due to the 164 
transfection process, a tetracycline-dependent stable line of the HBV replicon plasmid was 165 
established in CH12F3-2 cells (CH12-HBV; Fig. 3I). CH12-HBV cells were treated with CIT 166 
to induce IgA switching, and HBV transcript levels were determined. Subsequent qRT-PCR 167 
analyses demonstrated significant reductions of HBV transcript levels upon IgA switching 168 
(Fig. 3J–K). These data clearly demonstrate that endogenous AID expression sufficient to 169 
trigger CSR is also sufficient to downregulate HBV transcripts. 170 
Another putative activity of AID involves the initiation of somatic hypermutation (SHM) in 171 
immunoglobulin variable genes [8,9],[25] previously demonstrated that human BL2 B cells 172 
autonomously induce SHM, which is absent following AID gene disruption by gene targeting. 173 
Thus, we transiently transfected the HBV replicon plasmid into BL2 cells and compared 174 
HBV replication in Aicda+/+ and Aicda−/− BL2 cells. We previously demonstrated that 175 
nucleocapsid NC-DNA and core protein are suppressed in Aicda+/+ in comparison with 176 
Aicda−/− BL2 cells, although co-transfected GFP expression levels were similar in both cell 177 
types [26]. Using identical samples, we here showed that HBV transcript levels in Aicda+/+ 178 
BL2 cells were almost 50% of those in Aicda−/− BL2 cells (Fig. 3L).  179 
Both mouse and human B cell lines collectively demonstrated that endogenous AID activity 180 
that can initiate either CSR or SHM of immunoglobulin genes is sufficient to trigger 181 
downregulation of HBV transcripts. 182 
 183 
AID-mediated downregulation of HBV transcripts requires intact P protein structure 184 
To investigate the mechanism of AID-mediated downregulation of HBV transcripts, we 185 
initially focus on the viral P protein, because AID, P protein and HBV transcripts form RNP 186 
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complex [26]. In these experiments, we applied a mutant HBV replicon plasmid (pPB-ΔP, 187 
Fig. 4A) that expresses a mutant P protein lacking the C-terminal half including catalytic 188 
DNA polymerase and RNase H domains [26]. Transfection with pPB-ΔP did not support 189 
nucleocapsid DNA synthesis due to inhibition of reverse-transcription, although HBV 190 
transcription and core protein synthesis remained intact in Huh7 cells (Fig. 4C, lanes 1 and 4). 191 
AID-mediated downregulation of HBV transcripts was compared between pPB- and pPB-Δ192 
P-transfected Huh7 cells. As shown in Fig. 4C, AID-mediated downregulation of HBV 193 
transcripts was not observed in pPB-ΔP-transfected Huh7 cells, indicating that AID-194 
mediated downregulation of HBV transcripts requires intact viral P protein. 195 
 196 
The requirement of cytidine deaminase activity for AID was also investigated. AID mutant 197 
P19 was isolated from a class switch deficient patient and the deaminase activity was 198 
negligible owing to a missense mutation in catalytic cytidine deaminase domain [27]. P19 199 
was then co-transfected with the wild-type HBV plasmid, and HBV transcript levels were 200 
compared with that in wild-type AID controls. These experiments showed that the P19 201 
mutant significantly reduced HBV transcript level, although less effectively than wild-type 202 
AID (Fig. 4C). Therefore, under experimental conditions of AID over-expression, cytidine 203 
deaminase activity is not exclusively required for AID-mediated downregulation of HBV 204 
transcripts.  205 
 206 
In subsequent experiments, we generated an expression vector (pFLAG-PΔC) for the mutant 207 
P protein which was a corresponding mutant P protein produced from pPB-ΔP-transfected 208 
cells (Fig. 4B). Then the physical association between AID and the mutant P protein was 209 
examined. Immunoprecipitation analyses showed that wild type P protein co-precipitated 210 
AID in an RNase A-sensitive manner (Fig. 4D, lane 5, 8, 9), whereas the mutant P protein 211 
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(FLAG-PΔC) precipitated only trace levels of AID protein, suggesting that AID may not 212 
efficiently form RNP complex with the mutant P protein in pPB-ΔP-transfected cells. To 213 
explore which subcellular sites are responsible for AID and P protein interaction, cells were 214 
biochemically fractionated into three fractions (cytoplasmic, soluble nuclear, and insoluble 215 
nuclear) (Supplementary Fig. 3). Immunoprecipitation analyses using cytoplasmic and 216 
soluble nuclear proteins revealed that AID can associate with P protein in both nucleus and 217 
cytoplasm. It is of note that robust signals of AID and P proteins were found in the insoluble 218 
fraction that contains chromatin and other nuclear proteins. 219 
 220 
AID-mediated downregulation of HBV transcripts requires the RNA exosome complex  221 
AID was recently shown to physically interact with RNA exosome proteins and promote CSR 222 
in transcribed immunoglobulin genes [28,29]. The RNA exosome comprises a ring-like 223 
structure and two catalytic components, and plays a major role in various RNA processing 224 
and degradation pathways [30,31]. Exosome component 3 (Exosc3, also known as Rrp40) is 225 
non-catalytic but is essential for the degradation and processing of target RNA, and the 226 
knockdown of Exosc3 severely diminished the RNA exosome function [32]. Thus, we 227 
investigated whether Exosc3 is involved in TGF-β1-mediated downregulation of HBV 228 
transcripts in Huh7 cells. As shown in Fig. 5A, immunoprecipitation of AID co-purified 229 
Exosc3, but did not precipitate GAPDH or GFP. Exosc3 immunoprecipitation also co-230 
purified AID but not GAPDH or GFP (Fig. 5B), indicating a physical association between 231 
AID and Exosc3 proteins. This study found a physical association between AID and the RNA 232 
exosome proteins (Exosc 2, 3, 7) in Huh7 cells in the absence of HBV replication (Fig. 5D). 233 
As expected, Exosc3 immunoprecipition also copurified with other RNA exosome proteins 234 
(Exosc2 and 7) in Huh7 cells (Fig. 5D). Furthermore, we found that AID can also associate 235 
with RNA exosome in both nucleus and cytoplasm (Supplementary Fig. 4A). Consistent with 236 
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AID-RNA exosome interaction, RNA exosome proteins localized to both cytoplasm and 237 
nucleus (Supplementary Fig. 5A and B). We previously demonstrated a physical association 238 
between HBV transcripts and AID in HBV-replicating Huh7 cells [26]. In current study, we 239 
examined whether Exosc3 associates with HBV transcripts. As shown in Fig. 5C, qRT-PCR 240 
analysis demonstrated enrichment of HBV but not HPRT transcripts in Exosc3 241 
immunoprecipitates, which was observed only when AID was present (Fig. 5C, lane 1). This 242 
is also true when nuclear or cytoplasmic Exosc3 was separately precipitated (Supplementary 243 
Fig. 4B). AID-mediated downregulation of HBV transcripts was observed in both nucleus 244 
and cytoplasm, and efficiency of downregulation was comparable between nucleus, 245 
cytoplasm, and whole cell samples (Supplementary Fig. 6A and B). These results suggest that 246 
AID recruits the RNA exosome proteins to HBV transcripts and AID downregulates HBV 247 
RNA in nucleus. 248 
 249 
To further confirm that the RNA exosome is involved in AID-mediated downregulation of 250 
HBV transcripts, we used the siRNA knockdown of Exosc3, which is essential for the RNA 251 
exosome function [32]. In these experiments, siRNAs against Exosc3 were co-transfected 252 
with the HBV plasmid and AID (or GFP) expression vectors, and HBV replication was 253 
determined. Northern blotting, NAGE assays, and qRT-PCR analyses showed the attenuation 254 
of AID-mediated downregulation of HBV transcripts and nucleocapsid formation in siExosc3 255 
transfectants (Fig. 5E-G). In contrast, AID, GFP, and GAPDH expression were not affected 256 
by Exosc3 depletion (Fig. 5E, bottom). Importantly, knock down of Exosc3 did not increase 257 
HBV RNA levels in GFP transfected samples. Moreover, siExosc3 transfection attenuated 258 
TGF-β1-mediated downregulation of HBV transcripts and nucleocapsid formation in a 259 
similar manner to that observed after transfection with siAID (Fig. 6A-F). In further 260 
experiments, knockdown of another RNA exosome component Exosc6 also attenuated TGF-261 
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β1-mediated downregulation of HBV transcripts and nucleocapsid formation, albeit less 262 
effectively than the knockdown of siExosc3 and AID (Fig. 6A-F). Similarly, the contributions 263 
of AID and Exosc3 to TGF-β1-mediated downregulation of HBV transcripts were examined 264 
in stably HBV-transfected Huh7 cells (7T7-8) [26]. The short hairpin (sh) RNA expressing 265 
lentivirus was transduced into 7T7-8 cells, and two stable transfectants (shAID and 266 
shExosc3) and a control transfectant (shLuc) were established after puromycin selection. 267 
These cells were then cultured in the presence or absence of TGF-β1 (Fig. 7A). Subsequent 268 
qRT-PCR and western blotting showed reduced endogenous AID and Exosc3 expression (Fig. 269 
7B-E). Comparison of HBV transcript levels between TGF-β1-treated and non-treated 7T7-270 
8 cells revealed that TGF-β1-mediated reduction of HBV transcripts is restored by the 271 
knockdown of AID and Exosc3 (Fig. 7F). Taken together, these data indicate that RNA 272 
exosome proteins (Exosc3 and Exosc6) and AID are required for TGF-β 1-mediated 273 
downregulutation of HBV transcripts. 274 
 275 
AID-mediated downregulation of HBV transcripts depends on transcription 276 
Immunoglobulin gene diversification triggered by AID is coupled with the transcription of 277 
immunoglobulin locus [8,9]. Here we examined whether AID-mediated HBV RNA 278 
downregulation is also coupled with transcription using a transcription inhibitor actinomycin D 279 
(ActD). Using a stable HBV transfectant (7T7-8), we generated experimental conditions in 280 
which endogenous or ectopic AID is expressed in HBV-replicating cells. ActD was then added 281 
to evaluate whether it could downregulate HBV RNA even in ActD-treated cells. As shown in 282 
Fig. 8A and B, no significant synergistic reduction in HBV RNA levels by ActD and AID was 283 
observed in TGF-β1-treated and AID-overexpressing cells, indicating that AID was unable to 284 
reduce HBV RNA levels in ActD-treated cells. These results suggest that AID-mediated HBV 285 
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RNA downregulation depends on transcription, similar to the immunoglobulin gene 286 
diversification triggered by AID. 287 
 288 
Discussion 289 
AID is a key molecule involved in the diversification of immunoglobulin genes [8,9], and 290 
thus its role in B cells is well understood. AID expression has been also found in non-B cells 291 
[11-13], however, its role in non-B cells remains elusive. In the present study, we assessed 292 
AID involvement in TGF-β1-dependent anti-HBV activity and demonstrated the following: 293 
(1) AID expression is upregulated in TGF-β1-stimulated hepatocytes and reduces HBV 294 
RNA levels (Fig. 1 and 2); (2) TGF-β1-mediated downregulation of HBV transcripts is 295 
inhibited by AID knockdown (Fig. 2); and (3) endogenous AID protein levels in B cells 296 
capable of inducing immunoglobulin diversification also downregulate HBV transcript levels 297 
in a transcription-coupled manner (Fig. 3 and 8). These data indicate that AID is involved in a 298 
TGF-β1-mediated anti-HBV pathway. 299 
 300 
Which part of the virus life cycle that is targeted by AID-mediated downregulation of HBV 301 
transcripts? Another APOBEC protein, A3A, which was previously proposed to hypermutate 302 
transfected plasmids in human peripheral monocytes [33]. However, AID did not change 303 
HBV transcript levels in hepatocytes transfected with the mutant HBV replicon (pPB-ΔP) 304 
(Fig. 4C). In contrast, HBV transcripts in hepatocytes transfected with the wild-type replicon 305 
(pPB) were specifically downregulated by following the expression of AID expression (Fig. 2 306 
and 4). Intact HBV transcript levels in AID-expressing pPB-ΔP transfectants suggest that 307 
AID-mediated reduction of HBV transcripts is not due to plasmid targeting or promoter 308 
interference by AID activity. Otherwise, targeting of HBV plasmid or promoter activity 309 
would result in reduction of HBV transcripts in both pPB- and pPB-ΔP-transfectants 310 
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because those HBV plasmids share the exactly same DNA sequences except 4 base insertion 311 
within P gene in pPB-Δ P. Previous our study demonstrated that chicken AID can 312 
downregulate cccDNA of duck hepatitis virus in a uracil-DNA glycosylase (UNG)-dependent 313 
manner [34], therefore, the next obvious candidate for AID target is cccDNA of HBV. We 314 
determined cccDNA levels of transfectants using the rolling circle amplification (RCA) assay, 315 
which specifically amplifies circular DNA, including cccDNA. As per our results, cccDNA 316 
was clearly detected in a cccDNA-producing control cell line (HepG2.2.5) [10-15,35]; 317 
however, the HBV-replicating transfectants used in this study rarely produced cccDNA 318 
(Supplementary Fig. 7A and B). Therefore, the majority of the HBV transcripts produced 319 
from HBV transfectants in the present experimental systems are derived from HBV replicon 320 
plasmids and not from cccDNA. That means that targeting of cccDNA does not explain the 321 
observed downregulation of HBV transcripts in the present experimental systems. AID over-322 
expression was previously shown to deaminate nucleocapsid NC-DNA and encapsidated 323 
pgRNA [10,13,26]. However, because NC-DNA is reverse transcribed from HBV pgRNA, 324 
AID activity against NC-DNA fails to explain the downregulation of HBV transcripts. 325 
Reduction of HBV RNA by the catalytically dead mutant AID (p19) indicates that 326 
encapsidated pgRNA editing is distinct from AID-mediated reduction of HBV RNA. Thus, 327 
we concluded that AID directly targets HBV transcripts. 328 
 329 
The viral P protein is a reverse transcriptase that binds 5′-epsilon RNA structure in pgRNA 330 
and encapsidates pgRNA to the nucleocapsid [1,2] (see also Supplementary Fig. 1). It is 331 
demonstrated that P protein can also bind 3′-epsilon RNA structure present in 2.4-, 2.1-, and 332 
0.7-kb viral mRNAs [36], indicating that P protein binds all types of HBV transcripts. AID 333 
and TGF- downregulate HBV transcripts containing 3′-epsilon but not cellular transcripts 334 
(Figs. 1D, 4C, 5E, 6A, and Supplementary Figs. 1, 2). AID-mediated HBV RNA reduction 335 
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did not occur in hepatocytes expressing a mutant P protein (Fig. 4C). We demonstrated that 336 
AID can physically associate with viral RNP complexes comprising P protein [26] (Fig. 4). 337 
Therefore, AID-mediated HBV RNA reduction is dependent on the presence of intact P 338 
protein and P protein may determine the target specificity for AID-mediated HBV RNA 339 
reduction.  340 
 341 
Mao et al. recently reported that zinc finger antiviral protein (ZAP) inhibits the replication of 342 
HBV by binding the 5′-epsilon RNA structure of HBV and degrading viral RNA [37]. To 343 
explore the molecular mechanism of AID-mediated downregulation of HBV transcripts, we 344 
first investigated the possible involvement of ZAP. RT-qPCR revealed that AID expression 345 
did not affect the level of ZAP mRNA (Supplementary Fig. 2). Knocking down of ZAP by 346 
transfection of siRNAs against ZAP increased HBV RNA levels, which indicates that ZAP 347 
reduces the basal level of HBV RNA; however, AID-mediated downregulation of HBV 348 
transcripts was not affected by knocking down of ZAP expression (Supplementary Fig. 8). 349 
These results imply that the ZAP antiviral pathway is dispensable for AID-mediated 350 
downregulation of HBV transcripts.  351 
 352 
Next, we explored the possible involvement of the RNA exosome. Basu et al. [29] 353 
demonstrated that AID binds and recruits the RNA exosome complex to R-loop structures in 354 
immunoglobulin genes. Here, we investigated whether AID forms a complex with RNA 355 
exosome proteins in hepatocytes. The immunoprecipitation of AID and Exosc3 revealed the 356 
formation of a RNP complex comprising AID and RNA exosome proteins in both nucleus 357 
and cytoplasm of hepatocytes, and that HBV transcripts formed a specific complex with the 358 
RNA exosome in an AID-dependent manner (Fig. 5, Supplementary Fig. 4). Furthermore, 359 
AID-dependent downregulation of HBV transcripts was inhibited in the absence of the 360 
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essential RNA exosome component Exosc3 (Fig. 5). We also demonstrated that AID-361 
mediated downregulation of HBV transcripts does not occur when P protein loses the C-362 
terminus domain, which is essential for AID binding (Fig. 4C). Inhibition of transcription 363 
resulted in blocking of AID-mediated downregulation of HBV transcripts (Fig. 8). Taken 364 
together, we suggest that AID recruits the RNA exosome to transcribing HBV RNA through 365 
an association with the P protein, and thereby downregulates HBV transcripts (Fig. 8C).  366 
 367 
AID has been shown to reduce the transpositioning of the reverse transcriptase-dependent 368 
retroelement L1 [14,15]. Moreover, MacDuff et al. demonstrated that a catalytically dead 369 
mutant and wild-type AID suppress L1 transpositioning. Here, we showed that the AID-370 
mediated HBV RNA reduction depends on HBV reverse transcriptase (P protein), and 371 
catalytically dead mutant AID (p19) reduces HBV transcript levels (Fig. 4). It would be 372 
interesting to examine whether suppression of transpositioning by AID is also dependent on 373 
the RNA exosome. 374 
To our knowledge, this is the first study to show that AID mediates the downregulation of 375 
viral RNA through the RNA exosome complex. However, further studies are required to 376 
elucidate the mechanisms of AID-mediated HBV RNA downregulation, and to investigate the 377 
involvement of AID in anti-HBV activity in vivo.  378 
 379 
Materials and Methods 380 
NAGE assays 381 
NAGE assays were performed as previously described [20,26,38,39]. In brief, intact 382 
nucleocapsid particles were separated from crude extracts of HBV-replicating cells using 383 
agarose gel electrophoresis. Nucleocapsid particles within the gel were then denatured under 384 
alkaline conditions, and were transferred onto nitrocellulose membranes (Roche). 385 
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Nucleocapsid DNA and core proteins were detected using Southern and western blotting with 386 
a double-stranded HBV DNA probe spanning the whole viral genome and an anti-core 387 
antibody, respectively.  388 
Cell culture and transfection 389 
Plasmids were transfected into Huh7 cells using CalPhos (Clontech) or Fugene 6 (Roche). 390 
The total transfected plasmid per sample was normalized by supplementation with empty or 391 
GFP expression plasmids. Co-transfection of plasmid and siRNA was performed using 392 
lipofectamine 2000 according to the manufacturer’s instructions. Stealth-grade siRNA for 393 
mouse and human AID, A3A, A3G, Exosc3, Exosc6, and control were purchased from 394 
Invitrogen. In all transfection experiments, control siRNA was designed to differ from all 395 
mammal transcripts. BL2 [25] and CH12F3-2 cell culture, CIT stimulation, and transfection 396 
by electroporation were performed as previously described [24-26,40]. The HBV-replicating 397 
Huh7 cell line (7T7-8) was established and described previously [26]. The pTre-HBV [41] 398 
vector was transfected into tetracycline activator expressing CH12F3-2 cells (FTZ14 [42]) to 399 
establish the CH12-HBV cell line. Subsequently, shLuc, shAID, and shExosc3 expressing 400 
7T7-8 cells were established by infection with recombinant lentivirus followed by puromycin 401 
selection. Recombinant lentiviruses were generated by transient transfection of shLuc-, 402 
shAID-, and shExosc3-pLKO1-puro and packaging plasmids (pMD2.D and psPAX2, 403 
Addgene plasmid 12259 and 12260, respectively, kind gifts of Dr. Trono) in 293T cells 404 
according to the manufacturer’s instructions. 405 
 406 
Expression vectors and reagents 407 
Human TGF-β 1 and IL-4 were purchased from R&D systems. Actinomycin D was 408 
purchased from Sigma-Aldrich. The HBV replicon plasmid (pPB) contains 1.04 copies of 409 
HBV genomic DNA and expresses pgRNA under the control of the CMV promoter [21]. The 410 
 18 
pPB-ΔP plasmid contains a frame-shift mutation in codon 306 of the P gene, leading to loss 411 
of the C-terminal 539 amino acids, which comprise catalytic and RNase H domains [26]. 412 
Probe labeling and northern and Southern blots were developed using the AlkPhos direct 413 
labeling system (Amersham). Signals for northern, Southern, and western blots were 414 
analyzed using a LAS1000 Imager System (FujiFilm). Other expression vectors are listed in 415 
Supplementary Table S1. 416 
 417 
Immunoprecipitation and western blotting 418 
Cells were lysed in buffer containing 50-mM Tris-HCl (pH 7.1), 20-mM NaCl, 1% NP-40, 1-419 
mM EDTA, 2% glycerol, and protease inhibitor cocktail (Roche). After centrifugation, 420 
supernatants were incubated with the indicated antibodies and protein G sepharose (GE 421 
Healthcare) or anti-FLAG M2 agarose beads (Sigma, A2220). For IP-qRT-PCR experiments, 422 
cells were lysed with PBS containing 0.1% Tween 20, 1% triton-X, 1-mM EDTA, protease 423 
inhibitor cocktail (Roche), and 2% glycerol. After centrifugation, crude lysates were 424 
subjected to anti-FLAG M2 beads for 4 h. Immune complexes were washed in lysis buffer 10 425 
times and were then washed in lysis buffer containing an additional 100-mM NaCl. FLAG-426 
Exosc3 and RNA complexes were eluted using free 3 × FLAG peptides (Sigma, F4799). 427 
Western blotting was performed using standard methods with rabbit anti-GAPDH (Sigma, 428 
G9545), mouse anti-FLAG (Sigma, F3165), rabbit anti-GFP (Clontech, 632376), anti-rabbit 429 
Igs HRP (Biosource, ALI3404), anti-rat Igs HRP (Jackson ImmunoResearch, 712-035-153), 430 
rabbit and mouse IgG TrueBlot (eBioscience, 18-8816, 18-8877), rat monoclonal anti-AID 431 
(MAID2, eBioscience, 14-5959), rabbit anti-A3G[38], anti-core (Dako, B0586), anti-human 432 
Exosc3 (GenWay Biotech, GNB-FF795C, F8130F), and isotype control (eBioscience 14-433 
4321) antibodies. To generate a polyclonal antibody against AID, the C-terminal AID peptide 434 
(EVDDLRDAFRMLGF) was conjugated with cysteine and rabbits were immunized using 435 
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keyhole limpet hemocyanin (KLH). Subsequently, anti-AID rabbit serum and rat monoclonal 436 
anti-AID were isolated and used in IP experiments. IgA class switching was determined by 437 
detecting surface IgA expression using flow cytometry as previously described[7,24,40]. 438 
 439 
Quantitative PCR and RT-PCR 440 
Total RNA was extracted using TRIsure (Bioline), was treated with DNase I (Takara) to 441 
eliminate transfected plasmids, and was then re-purified using TRIsure. For qRT-PCR 442 
analyses, 1 µg of total RNA was treated with amplification grade DNase I (Invitrogen) and 443 
was then reverse-transcribed using oligo-dT or random primers with SuperScript III 444 
(Invitrogen). Subsequently, cDNA was amplified using SYBR green ROX (Toyobo) with 445 
MX3000 (Stratagene) according to the PCR protocol. A1, AID, A3A, A3B, A3C, A3D, A3F, 446 
A3G, A3H, Exosc3, Exosc6, 18S ribosomal RNA, HPRT, and β-actin expression and HBV 447 
transcription were determined using PCR conditions of 95°C for 1 min followed by 40 cycles 448 
of 95°C for 15 s, 55°C for 30 s, and 70°C for 30 s, and one cycle of 95°C for 1 min, 55°C for 449 
30 s, and 95°C for 30 s. For A3A amplification, an annealing temperature of 60°C was used. 450 
Copy numbers of APOBECs were determined using plasmid standard curves for each 451 
APOBEC (Fig. 2A). Fold induction of APOBEC expression following treatment of cells with 452 
TGF-β1 was determined using the ΔΔCT method [43]. To eliminate transfected plasmids, 453 
purified NC-DNA from secreted virions and cytoplasmic lysates was obtained after serial 454 
DNase I digestion, proteinase K and SDS digestion, phenol–chloroform extraction, and 455 
isopropanol precipitation. NC-DNA copy numbers were determined using a HBV plasmid 456 
standard curve. Transcript expression levels in this study (except Fig. 2A) are presented as 457 
fold induction relative to unstimulated cells. In transfection experiments, expression levels of 458 
mock-, GFP-, siGFP-, and siLuc-transfected cells were defined as one. Expression levels in 459 
qRT-PCR analyses were normalized to the amplification of internal controls (HPRT, β-actin, 460 
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or 18S ribosomal RNA). Primers are listed in Supplementary Table S2. 461 
 462 
Statistical analysis 463 
Differences were identified using the two-tailed unpaired Student’s t-tests and were 464 
considered significant when P < 0.05. 465 
 466 
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FIGURE. LEGENDS 597 
Figure 1. TGF-β1 upregulates APOBEC3 expression and suppresses HBV replication 598 
in Huh7 cells  599 
Six hours after transfection of pPB, Huh7 cells were treated with TGF-β1 for 3 days, and 600 
HBV replication was evaluated. (A) qRT-PCR shows dose-dependent reduction of HBV 601 
transcripts by TGF-β1. (B) NC-DNA levels in secreted virions were also measured using 602 
qPCR. (C) Nucleocapsid NC-DNA and core protein levels in crude cytoplasmic extracts were 603 
assessed using NAGE assays. GAPDH protein levels in the same crude extracts were 604 
determined using western blotting. (D) Huh7 cells were treated with 150 ng/mL IL-4 or 10 605 
ng/ml TGF-β1 for 3 days. Levels of HBV RNA and GAPDH mRNA were determined by 606 
Northern blot. Control: non-stimulated Huh7 cells. (E) Relative expression levels of 607 
APOBEC deaminases in non-stimulated Huh7 cells; Relative expression levels were 608 
determined using qPCR with cDNA from non-stimulated Huh7 cells and standard curves of 609 
control APOBEC deaminase DNA. Relative copy numbers of A3B were defined as one. (F) 610 
Induction of APOBEC deaminase expression in TGF-β1-treated Huh7 cells was estimated 611 
using qRT-PCR. Fold induction of APOBEC deaminases is shown in the top (10 ng/mL TGF-612 
β1 for 24 or 48 h) and bottom (10 or 20 ng/mL TGF-β1 for 24 h) panels. (G) Huh7 cells 613 
were treated with indicated concentrations of TGF-β 1 for 3 days. AID protein was 614 
immunoprecipitated using an anti-AID antibody (or an isotype control IgG, most right) and 615 
immunoprecipitated AID protein was determined by western blot. One lane contains 616 
immunoprecipitated protein harvested from 60% of 15 cm dish. All data are representative of 617 
two to four independent experiments. Error bars represent standard errors of the mean. 618 
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 619 
Figure 2. AID is responsible for TGF-β1-mediated reduction of HBV transcripts 620 
To evaluate antiviral activity of indicated APOBEC proteins, Huh7 cells were co-transfected 621 
with FLAG-tagged A3A, A3C, A3F, A3G, GFP or GFP-tagged AID expression vectors and 622 
pPB. Cells were cultured for 3 days, and then HBV replication was estimated using NAGE 623 
assays (A). Protein expression is shown (A, bottom). qRT-PCR analyses of HBV transcripts 624 
(B), and qPCR analyses of NC-DNA in secreted virions (C). (D), Secreted virions in the 625 
culture medium and cytoplasmic extracts were treated with proteinase K and SDS to digest 626 
nucleocapsids, and levels of HBV DNA were determined using Southern blotting. (E), To 627 
evaluate contribution of indicated APOBEC proteins, Huh7 cells were co-transfected with 628 
pPB and the indicated siRNAs. Six hours later, cells were incubated in the presence or 629 
absence of 10 ng/mL TGF-β1. Three days later, total RNA was extracted, and qRT-PCR 630 
performed to determine expression levels of HBV transcripts, AID, A3A, and A3G. Although 631 
siAID significantly reduced AID expression and prevented the downregulation of HBV 632 
transcripts in TGF-β1-stimulated Huh7 cells (lane 1), siA3A and siA3G had no effects 633 
against the downregulation of HBV transcripts (lanes 2–4). siGFP was used as a control. 634 
Expression levels in lane 8 are defined as one fold induction. **P < 0.01 (t-test); Data are 635 
representative of two to three independent experiments and error bars represent standard 636 
errors of the mean. 637 
 638 
Figure 3. IgA switching activity correlates with reduction of HBV transcripts in B cells 639 
(A, B, C, D) pPB and GFP expression vectors were transiently co-transfected into a mouse B 640 
cell line (CH12F3-2). Six hours after transfection, cells were divided into two groups and 641 
stimulated with (or without) CD40 ligand, IL-4, and TGF-β1 (CIT) for 3 days to induce IgA 642 
switching; (A) Schematic diagram of experimental design; (B) Nucleocapsid formation was 643 
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measured using NAGE assays and GFP expression was used to confirm transfection. (C) 644 
HBV transcripts and AID expression levels were determined using qRT-PCR. (D) AID 645 
dependent IgA switching was determined using flow cytometry. (E, F, G, H) CH12F3-2 cells 646 
were co-transfected with pPB and the indicated siRNA against mouse AID (simAID-1 and -2) 647 
or controls (siCtrl and siGFP), and after 6 hours incubation, cells were further stimulated with 648 
CIT for 3 days. HBV transcript levels, knock down efficiency of AID, and IgA switching 649 
were determined using qRT-PCR, western blotting, and flow cytometry, respectively. (I, J, K) 650 
A tetracycline promoter-regulating HBV plasmid (pTre-HBV) was stably transfected into 651 
CH12F3-2 transfectants expressing tetracycline-responsible transactivator (Tet-off). 652 
Established CH12F3-2 transfectants were designated CH12-HBV; (I) Schematic diagram of 653 
CH12-HBV; (J) CH12-HBV cells were incubated in the presence or absence of CD40 ligand, 654 
IL-4, or TGF-β1 (CIT) and tetracycline as indicated for 2 days to induce endogenous AID 655 
expression and IgA switching. HBV transcription and AID expression levels were determined 656 
using qRT-PCR. (K) IgA switching was detected according to surface expression of IgA using 657 
flow cytometry. (L) AICDA-deficient and -wild type BL2 cells were transfected with HBV 658 
plasmid (pPB), and qRT-PCR was performed at 3 day post-transfection. *P < 0.05, **P < 659 
0.01 (t-test). Data are representative of two to three independent experiments and error bars 660 
represent standard errors of the mean. 661 
 662 
Figure 4. Intact P protein is required for AID-mediated downregulation of HBV 663 
transcripts and AID associates with HBV P protein. 664 
(A) Schematic diagram of wild-type and mutant HBV replicon plasmids. Partially redundant 665 
HBV genomic DNA is shown as black boxes and the positions of 5ʹ -ε and 3ʹ -ε are 666 
shown. Open reading frames corresponding to C, P, S, and X genes are shown as open boxes. 667 
The position of the frame-shift mutation in the mutant replicon plasmid (pPB-ΔP) is 668 
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indicated as an open triangle. This frame-shift mutation results in loss of the C-terminal 669 
portion (polymerase and RNase H domains) from the P protein; pCMV, CMV promoter. (B) 670 
Schematic diagram of P protein domain structure; (C) Replicon plasmid (pPB or pPB-ΔP) 671 
and GFP fusion expression vectors (mock, AID, and p19-mutant AID) were transfected into 672 
Huh7 cells, and after four days, AID-mediated downregulation of HBV transcripts was 673 
compared between two replicon plasmids or between wild-type and p19 mutant AID using 674 
northern blotting. Expression of HBV core and GFP fusion proteins (mock, AID, and p19-675 
mutant AID) was confirmed using SDS-PAGE and western blotting. (D) Wild-type replicon 676 
plasmid (pPB) and indicated protein expression vectors (FLAG-P, FLAG-PΔC, or AID) 677 
were transfected into Huh7 cells. Three days later, physical associations between AID and 678 
FLAG-P (or FLAG-PΔC) proteins were determined using immunoprecipitation (IP). In lane 679 
9, crude extract was incubated with RNase A before immunoprecipitation. Positions of 680 
FLAG-P and FLAG-PΔC proteins are indicated by arrows and diamonds, respectively. The 681 
structure of FLAG-PΔC protein is shown in B. Input; crude extract. Data are representative 682 
of two to three independent experiments. 683 
 684 
Figure 5. AID inducing HBV RNA reduction depends on Exosc3 685 
(A, B) Huh7 cells were co-transfected with pPB and the indicated protein expression vectors, 686 
and were cultured for 3 days. Crude extracts (input) were then subjected to IP using an anti-687 
FLAG antibody, and crude extracts and IP fractions were analyzed using western blotting. (C) 688 
Fold enrichment of HBV or HPRT transcripts upon anti-FLAG-Exosc3 IP; To determine 689 
RNA coprecipitation with the RNA exosome component Exosc3, Huh7 cells were transfected 690 
with pPB, pFLAG-Exosc3, and pCMV-AID (or pEGFP-C2), and were cultivated for 3 days. 691 
IP using anti-FLAG antibody was then performed, complexes of FLAG-Exosc3 were then 692 
eluted using free FLAG peptides, and the eluted RNA was analyzed using qRT-PCR. 693 
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Combination of expression vectors used for transfection is the same with B (see numbers 694 
below the graph), and values in lane 3 were defined as 1. Error bars represent standard errors 695 
of the mean. (D) Associations of AID with RNA exosome proteins; Huh7 cells were co-696 
transfected with indicated expression vectors, and were cultured for 3 days. Crude extracts 697 
(input) were subjected to IP with FLAG antibody, and crude extracts and IP fractions were 698 
analyzed using western blotting. Expression levels of GFP-Exosc7 were too low to be 699 
visualized in the crude extract (lanes 4 and 9, input), but GFP-Exosc7 was clearly detectable 700 
after FLAG-AID and FLAG-Exosc3 immunoprecipitation (lanes 4 and 9, IP). (E) Huh7 cells 701 
were co-transfected with pPB and either AID or GFP expression vectors and each of the 702 
siRNAs indicated in E and F, and cells were cultured for 3 days. HBV transcript levels, 703 
nucleocapsid formation, and Exosc3 expression were estimated using northern and western 704 
blotting, NAGE assays (E), and qRT-PCR analyses (F and G); siGFP and siCtrl were used as 705 
controls; **P < 0.01 (t-test); Data are representative of two to three independent experiments 706 
and error bars represent standard errors of the mean.  707 
 708 
Figure 6. TGF-β1-mediated downregulation of HBV transcripts requires RNA exosome 709 
proteins 710 
Huh7 cells were transfected with pPB and indicated siRNAs. Six hours after transfection, the 711 
cells were incubated in the presence or absence of 10-ng/mL TGF-β1 for 3 days. Total RNA 712 
was analyzed using northern blotting (A) and qRT-PCR to determine HBV transcription of 713 
AID, Exosc3, and Exosc6 (B, D, E, F). In C, NC-DNA from secreted virions was also 714 
measured by qPCR. Transfection of siAID and siExosc3 partially restored TGF-β1-mediated 715 
downregulation of HBV transcripts and viral production; *P < 0.05, **P < 0.01 (t-test); error 716 
bars represent standard errors of the mean. Data are representative of two to three 717 
independent experiments. 718 
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 719 
Figure 7. TGF-β1-mediated reduction of HBV transcripts depends on AID and Exosc3 720 
Stable HBV transfectant Huh7 cells (7T7-8) were infected with recombinant lentiviruses to 721 
express indicated short hairpin (sh) RNA, and then cells were incubated in the presence or 722 
absence of 15 ng/ml TGF-β1 for 3 days. (A) Schematic diagram of experimental design; (B) 723 
AID expression levels in qRT-PCR and (C) IP western blotting. Crude extract before IP was 724 
also blotted (input). Crude extracts from TGF- β 1-treated 7T7-8 transfectants were 725 
immunoprecipitated by anti-AID antibody. Loading control: anti-(adenosine deaminase 726 
acting on RNA) ADAR. (D) Exosc3 expression level in qRT-PCR or western blotting (E); 727 
shLuc was used as a control; (F) Reductions of HBV transcript levels following TGF-β1 728 
treatment are compared between shAID-, shExosc3-, and shLuc-expressing 7T7-8 cells. HBV 729 
transcript levels of each non-stimulated transfectant are defined as 1; shLuc was used as a 730 
non-targeted control. *P < 0.05, **P < 0.01 (t-test), error bars represent standard errors of the 731 
mean. Data are representative of two to three independent experiments. 732 
 733 
Figure 8. Transcription dependency for TGF- β 1-mediated reduction of HBV 734 
transcripts and a proposed model  735 
 736 
 HBV-expressing 7T7-8 cells were treated with 10 ng/ml TGF-β1 (A) or transfected with 737 
AID (or GFP) expression plasmid (B) and cultivated for 3 days. At 18 h before harvest, 100 738 
ng/ml actinomycin D (ActD) was added to block transcription. Total RNA was extracted to 739 
measure HBV RNA levels (normalized by HPRT) by qRT-PCR. HBV RNA levels in non-740 
treated (A) and GFP transfected cells (B) were taken as one. **P < 0.01 (t-test); Data are 741 
representative of two independent experiments and error bars represent standard errors of the 742 
mean. (C) Hypothetical model: Left panel, the canonical HBV life cycle; (a) After the entry 743 
of HBV into a hepatocyte, nucleocapsid NC-DNA is converted into cccDNA. (b) 744 
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Subsequently, cccDNA expresses viral transcripts, including pgRNA, pre-S1, pre-S2/S, X, 745 
and pre-C mRNAs. In this study, most viral RNAs were transcribed from the HBV plasmid 746 
instead of cccDNA. All transcripts possess the 3ʹ -ε RNA stem-loop structure; only pgRNA 747 
is shown. (c) P protein binds to the ε  structure and stabilizes it, and the core protein 748 
(indicated by hexagons) is then recruited to form the nucleocapsid. (d) Inside the 749 
nucleocapsid, P protein reverse transcribes pgRNA to produce NC-DNA. A mature 750 
nucleocapsid gains S proteins and is secreted as an infectious virion. The minor fraction of 751 
nucleocapsid may enter a second intracellular viral cycle. (e) Right panel, TGF-β 1 752 
stimulation of hepatocytes induces AID expression. (f) AID associates with the RNA 753 
exosome proteins. The RNA exosome comprises ring-like core and exonuclease catalytic 754 
components. AID associates with HBV transcripts and P proteins. (g) Consequently, AID 755 
bridges the RNA exosome with the RNP complex of HBV transcripts and P protein, which 756 
may trigger the degradation of HBV transcripts.  757 
 758 
 759 
Supplementary Results 760 
Supplementary Figure 1. AID suppresses all HBV transcripts.  761 
(A) Schematic diagram of putative HBV transcripts. Structure of the HBV replicon plasmid 762 
(pPB) is shown on the top. Red arrows indicate the position of the X gene primers. The 763 
putative HBV transcripts are depicted on the bottom. (B, C) qRT-PCR analysis of HBV RNA. 764 
The RNA samples used in Figure 2B and 2E (lanes 4 and 8) were subjected to qRT-PCR 765 
analysis using the X gene primers. **P < 0.01 (t-test). Data are representative of two to three 766 
independent experiments and error bars represent standard errors of the mean. 767 
Supplementary Figure 2. AID does not downregulate host cell gene expression.  768 
qRT-PCR analysis of cellular gene expression. The RNA samples used in Figure 2B were 769 
subjected to qRT-PCR analysis using the indicated gene primers. Expression levels of control 770 
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GFP-expressing cells are defined as 1-fold. Error bars represent standard errors of the mean. 771 
Supplementary Figure 3. AID binds to P protein in both the cytoplasm and nucleus in 772 
HBV replicating hepatocytes  773 
Huh7 cells were transfected with the indicated expression vectors and pPB. Two days after 774 
transfection, cells were harvested and biochemically separated into three fractions 775 
(cytoplasmic, soluble nuclear, and insoluble nuclear fractions) using the Subcellular Protein 776 
Fractionation Kit (Thermo Scientific) as recommended by the manufacturer. 777 
Immunoprecipitation with FLAG agarose M2 beads was performed. Expected positions for 778 
AID-GFP and GFP proteins are indicated at the left side of the anti-GFP blot. PCNA is a 779 
putative soluble nuclear protein and was used as a control. Interaction of AID with P protein 780 
was determined by Western blot analysis. 781 
Supplementary Figure 4. AID binds to Exosc3 in both the cytoplasm and nucleus in 782 
HBV replicating hepatocytes.  783 
Huh7 cells were transfected with the indicated expression vectors and pPB. Two days after 784 
transfection, cells were harvested and biochemically separated into three fractions 785 
(cytoplasmic, soluble nuclear, and insoluble nuclear fractions) using the Subcellular Protein 786 
Fractionation Kit (Thermo Scientific) as recommended by the manufacturer. 787 
Immunoprecipitation with FLAG agarose M2 beads was performed. Expected positions for 788 
AID-GFP and GFP proteins are indicated at the left side of the anti-GFP blot. Interaction of 789 
AID with Exosc3 was determined by Western blot analysis (A). Transcripts in the indicated 790 
fractions in A were subjected to RT-PCR analysis to determine coprecipitation of HBV and 791 
HPRT transcripts (B). 792 
Supplementary Figure 5. Subcellular localization of the RNA exosome proteins. 793 
GFP expression of Huh7 transfectants used in Figure 5D was observed by fluorescence 794 
microscopy. GFP expression of the transfectants in Figure 5D (lanes 1–4 and 6–9) are shown 795 
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in (A) and (B), respectively. GFP-tagged Exosc3, 2, and 7 are localized in both the cytoplasm 796 
and nucleus. A nuclear pattern of a GFP fusion protein is observed in some cells, especially in 797 
GFP-Exosc2- and -Exosc7-expressing cells. 798 
Supplementary Figure 6. AID downregulates HBV RNA in the nucleus. 799 
Huh7 cells were transfected with an AID-GFP (or GFP) expression vector and pPB. Two days 800 
after transfection, cells were harvested and biochemically separated into three fractions 801 
(soluble cytoplasmic, soluble nuclear, and whole cell extract) using the Subcellular Protein 802 
Fractionation Kit (Thermo Scientific) as recommended by the manufacturer. Expression of 803 
AID-GFP, GFP, and PCNA were detected by western blot (A) and HBV RNA levels were 804 
determined by qRT-PCR analysis (B). *P < 0.05, **P < 0.01 (t-test), error bars represent 805 
standard errors of the mean. Levels of HBV RNA from GFP transfectants were defined as 806 
one. 807 
Supplementary Figure 7. cccDNA level in Huh7 cells transfected with HBV replicon 808 
plasmids. 809 
Rolling circle amplification (RCA) is capable of amplifying circular DNA such as HBV 810 
plasmid and cccDNA. cccDNA production in pPB-transfected Huh7 cells and 7T7-8 cells 811 
was compared with that in cccDNA-producing cells (HepG2.2.15). (A) Schematic diagram of 812 
RCA and analysis of cccDNA is shown. (B) Huh7 cells were transfected with pPB (or pPB-813 
dP) and cultivated for 3 days. Huh7T7-8 cells were cultivated in the absence of tetracycline 814 
for 3 days. HepG2.2.15 cells were used as a cccDNA producing control cells. Nuclear 815 
fraction of each transfectant was subjected to Hirt extraction to extract cccDNA. cccDNA 816 






 copies of HBV plasmids 817 
were amplified side by side as a standard reaction. Amplified RCA products were digested by 818 
EcoRI (for plasmid standard reactions, EcoRV) and agarose electrophoresis image visualized 819 
by ethidium bromide is shown (top). EcoRI digestion converts concatemeric cccDNA into 3.2 820 
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kb monomer, while EcoRV digestion converts concatemeric HBV plasmids into 3.2-kb and 821 
4.2-kb DNA. Nucleocapsid production of each transfectants was also determined by 822 
extraction of nucleocapsid RC-DNA following PCR detection of HBV DNA (bottom). 823 
Supplementary Figure 8. Knocking down of ZAP expression did not affect AID-824 
mediated downregulation of HBV transcripts. 825 
  Huh7 cells were transfected with an AID (or GFP) expression vector with indicated siRNA 826 
together with pPB. Cells were harvested after 3 days of incubation. Levels of ZAP expression 827 
and HBV RNA were determined by RT-qPCR. siZAP-1 and -2 were obtained from Invitrogen. 828 
siZAP-3 [37] was obtained from Santa Cruz Biotechnology. (A) Fluorescence microscopic 829 
image of GFP transfectants on day 3 after transfection. Knocking down of GFP expression is 830 
obvious in siGFP transfectants. (B) ZAP mRNA expression levels. The expression level of 831 
ZAP in the GFP-transfected, GFP siRNA (siGFP)-transfected (far right) was defined as one. 832 
(C) HBV RNA levels: HBV RNA level in the GFP-transfected, GFP siRNA (siGFP)-treated 833 
(far right) was defined as one. AID expression reduces HBV RNA levels in both siZAP and 834 
siGFP transfectants. (D) HBV RNA levels: The same data set in (C) was plotted with HBV 835 
RNA levels in siGFP-AID and siGFP-GFP transfectants defined as one. Knocking down of 836 
ZAP increases HBV RNA levels in both AID and GFP transfectants. **P < 0.01 (t-test), error 837 
bars represent standard errors of the mean. 838 
 839 
Table S1. List of plasmids used in this study. 840 
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